Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma

• Status: Active, not recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate whether the combination of gemcitabine and paclitaxel allows to improve the overall survival compared to gemcitabine alone, in patients with metastatic Pancreatic Ductal Adenocarcinoma (PDAC) after FOLFIRINOX failure or intolerance.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UNICANCER
• Treatments: Albumin-Bound Paclitaxel; Gemcitabine; Paclitaxel

Criteria

Inclusion Criteria:

• Metastatic Pancreatic Ductal Adenocarcinoma with histological or cytological proof

• Age ≥18 years

• At least 1 evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 outside any previously irradiated area

• Failure of first line FOLFIRINOX (Progressive disease during therapy of within 3 months +/- 15 days)

• Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2

• Life expectancy ≥12 weeks

• Negative serology (HIV, hepatitis B and C)

• Adequate organs function

• Proven Post-menopausal status or negative urinary or serum pregnancy test

• Woman of childbearing potential and male patients must agree to use adequate contraception fo the duration of the trial and up to 6 months after completing treatment

• Patients affiliated to the social security system

• Patient must have signed a written informed consent form

Exclusion Criteria:

• Any other primary tumor or secondary malignancy except basal cell carcinoma of skin or in situ carcinoma of the cervix uteri

• Known cerebral metastasis

• Uncontrolled severe infections

• Patients with Kaposi's sarcoma

• Peripheral neuropathy exceeding grade 2 on Common Terminology Criteria for Adverse Events (CTCAE) v5.0

• Previous treatment with taxane and/or gemcitabine (for pancreas cancer only)

• Patients with known allergy or severe hypersensitivity to any trial drug or drug excipient

• Patients with any other disease or illness which requires hospitalisation or is incompatible with the trial treatment

• Patients unable to comply with trial obligations for geographic, social or physical reasons, or who are unable to understand the purpose and procedures of the trial

• Participation in another clinical trial within 14 days prior to randomization

• Patients deprived of liberty or under legal protection measures or patients whose willingness to participate in the trial may be unduly influenced